Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. by Innes, A, Beattie, R, Sergeant, R, Damaj, D, Foroni, L, Marin, D, Kanfer, E, Mielke, S, Milojkovic, D, MacDonald, D, Pavlu, J, Rahemtulla, A, Roberts, I, Slade, D, Bray, E, Goldman, J, Apperley, J, Szydlo, R, Dazzi, F, Rezvani, K